IBN Initiates Coverage of Apimeds Pharmaceuticals US, Inc.

Apimeds Pharmaceuticals US (NYSE American: APUS), a clinical-stage biopharmaceutical company developing non-opioid therapies for pain management, has engaged IBN to enhance its corporate communications strategy. The company's subsidiary, MindWave Innovations, is developing blockchain-based institutional digital asset infrastructure combining custody, reporting, and portfolio management for Bitcoin reserves and digital asset participation.